A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Trial details
- Registry ID
- NCT05506943
- Drugs studied
- CTX-009, Paclitaxel
TrialRedline tracks 2 clinical trials sponsored by Compass Therapeutics: 1 Phase 2 / 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943 | CTX-009, Paclitaxel | Active not recruiting | 2027-08-31Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNCT05513742 | CTX-009 | Completed | 2025-05-15Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Best Overall Response Description: Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1 Time frame: From randomization to treatment discontinuation for any reason, average 6 months. After: Measure: Best Overall Response Description: Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions. Time frame: From randomization to treatment discontinuation for any reason, average 6 months.
Before: 1 Dec 2026. After: 31 Aug 2027.
Before: Actual. After: Estimated.
Before: 21 Jan 2026. After: 1 Dec 2026.
Before: Completed. After: Active not recruiting.
NCT05513742 · Compass Therapeutics
Before: 28 Apr 2025. After: 15 May 2025.
Before: Estimated. After: Actual.
Before: 150 participants (planned). After: 168 participants (actual).
Before: Estimated. After: Actual.
Before: Jul 2025. After: 21 Jan 2026.
Before: Active not recruiting. After: Completed.